A clinical trial of a potential treatment for Ebola has started in Liberia, with the first Ebola patient receiving the study drug on 2 January. The trial aims to evaluate the effectiveness of brincidofovir in patients with Ebola virus disease. Professor Peter Horby the trial's chief Investigator, says: 'I'm delighted that the trial has started. We can only fully evaluate potential Ebola therapies during an epidemic, and we have shown that this is possible, even during the worst epidemic in living memory.' Professor Trudie Lang says: 'There are currently no known treatments for Ebola. Giving drugs on a case by case basis does not enable us to learn whether or not the possible treatments work, therefore it is essential that we run a properly designed trial to be able to test these drugs and see if they are safe and do in fact work.'
Today’s Research Excellence Framework (REF 2014) results confirm the University of Oxford’s world leading position in medical sciences research. Clinical Medicine ranked top for the overall quality of submissions along with Public Health Service, and Primary Care and Psychology, Psychiatry and Neuroscience. The University of Oxford overall has the largest volume of world leading research and impact submitted to the REF exercise.
In mid-Nov, in recognition of his 35 years of work fighting malaria in the conflict zones of the Thai-Myanmar border and for bringing around the same table Karen and Burmese representatives to discuss malaria elimination, François Nosten, director of the Shoklo Malaria Research Unit (SMRU), was awarded the 2014 TWAS Regional Prize for Science ...
Professor Trudie Lang, Director of the Global Health Network, Centre for Tropical Medicine and Global Health at The University of Oxford, is interviewed by Sky News about the news that trials are to begin into drugs to help with the treatment of Ebola.
A clinical trial is to be carried out in West Africa to see whether a novel antiviral drug called brincidofovir is effective against Ebola, subject to regulatory approval. The trial, involving an international team led by Oxford University scientists, will take place in an Ebola treatment centre run by Médecins Sans Frontières (MSF). Brincidofovir is an experimental antiviral drug made by Chimerix of Durham in North Carolina, USA.
13th November 2014, John Radcliffe Hospital, Lecture Theatre 1. Featuring: Dr Andrew Brent, Prof David Warrell, Prof Pierro Olliaro, Dr Anna Seale, Dr Paul Newton and Prof Kevin Marsh. 9am to 2pm.
Report on the growth of drug-resistant strains of disease features Professor François Nosten of the Shoklo Malaria Research Unit. Researchers at the Unit have identified that 40 per cent of patients are carrying an artemisinin-resistant form of malaria. The problem is spreading to neighbouring countries and could soon reach India and Bangladesh. Professor Nick White says that if the strain spreads to Africa, subsequent deaths could be measured in the hundreds of thousands, if not millions. Report is at 2.40.01 of the program.
Last week’s 25 years celebrations at KEMRI - Wellcome Trust, Centre for Geographic Medicine Research - Coast Kilifi County, Faith Osier and Abdisalan Noor were awarded awarded the title of visiting professors at the University of Oxford. This announcement came from Professor Sir Peter Ratcliffe at the 25 years of KWTRP celebrations in ...
The Centre for Geographic Medicine Research - Coast, Kilifi County was abuzz with activity last week. KEMRI - Wellcome Trust Research Programme was celebrating 25 years of Health Research in Kenya. The climax of the event saw the commissioning of the Mbuyuni Training Complex by H.E. President Uhuru Kenyatta at the KEMRI-Wellcome Trust complex in ...
Dr Peter Horby is leading the initiative to allow candidate Ebola treatments to be assessed rapidly in patients so that those proving safe and effective may be adopted for use as soon as possible. Dr Horby has now arrived in Guinea and is leading a four-strong group aiming to fast-track trials at treatment centres in West Africa. They are hoping to start the trials some time in November.